Sputnik V, the Russian vaccine against Covid-19, has given positive results in your first human trial. According to the scientific journal 'The Lancet', preliminary results of clinical trials show that it has not caused adverse incidents and generates antibodies.
The tests were carried out in two Russian hospitals with adults between 18 and 60 years old, which were isolated when they registered to participate in clinical trials and remained in medical centers for the first 28 days. The study details the first findings from two early-stage clinical trials, in which 76 people have participated.
According to the expert group, no serious adverse reactions were identified in more than 42 days and antibody responses were induced in all participants within 21 days. The secondary results of the trials also led to the belief that the vaccines produce, within 28 days, T-cell responses, which detect and kill invading pathogens or infected cells.
Regarding the next steps of the investigation, phase three of the vaccine clinical trial will include 40,000 volunteers of different age and risk groups and will be carried out with constant vigilance.
On the other hand, the World Health Organization (WHO) has stated this Friday that it is most likely that we will have to wait until mid-2021 for mass vaccinations against Covid-19 to be carried out. "Realistically, we don't expect to see mass vaccinations until the middle of next year."
. (tagsToTranslate) Russian vaccine (t) against (t) Covid (t) generates (t) antibodies (t) first (t) trial (t) human (t) Category: All (t) Category: Europe Report (t) Category: International News (t) Category: Others (t) Category: Pulses (t) Category: Pulses Europe